Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 05 Sep 2018 Status changed from active, no longer recruiting to completed.
- 05 Sep 2018 Planned End Date changed from 27 Aug 2018 to 30 Aug 2018.
- 22 Aug 2018 Planned primary completion date changed from 20 Aug 2018 to 24 Aug 2018.